Canadian real-world study to evaluate semaglutide's impact on glycemic control and weight in type 2 diabetes
Background
For patients with type 2 diabetes (T2D), Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer an effective non-insulin injectable therapy. While semaglutide (Ozempic®) has demonstrated superior HbA1c reduction and body weight loss in controlled clinical trials compared to placebo and other antihyperglycemic agents, there remains a significant gap in real-world evidence. Understanding its effectiveness in routine clinical practice, where patient populations and adherence may differ from trial settings, is crucial for optimizing T2D management and informing healthcare decisions.
Study Design
This retrospective cohort study will leverage the Canadian LMC Diabetes Registry to analyze real-world outcomes. Researchers plan to examine patients with type 2 diabetes who initiate once-weekly semaglutide subcutaneously as part of routine clinical care within a Canadian diabetes specialist practice group. The study aims to assess the effects of semaglutide on glycemic control (measured by HbA1c), body weight, and other relevant clinical outcomes. The design focuses on observing patients under usual care conditions to reflect practical effectiveness.
Why It Matters
Understanding semaglutide's real-world effectiveness is crucial for clinicians and patients beyond controlled trial settings. While clinical trials establish efficacy, real-world data can reveal how factors like adherence, comorbidities, and diverse patient populations influence outcomes. This study, once completed, will provide valuable insights into the practical utility of once-weekly semaglutide in routine Canadian diabetes care, potentially informing prescribing patterns and patient expectations for glycemic control and weight management. It will help bridge the gap between highly controlled research and everyday clinical practice, offering a more complete picture of semaglutide's benefits.
semaglutide
type-2-diabetes
real-world-evidence
glycemic-control
weight-loss
cohort-study